Yonjin Venture

OncoResponse is an immuno-oncology biotech company that is leveraging its proprietary human antibody platform to discover novel targets and identify fully human monoclonal antibodies as therapeutics for the treatment of cancers. It identifies genuine human antibodies to a variety of high-value targets linked with immunosuppressive myeloid biology. OncoResponse's antibody pipeline is expected to alleviate TME immunosuppression and boost immune activation, turning cold tumors hot.

NanoCellect Biomedical develops and delivers microfluidic-based solutions that are affordable, compact, and easy to use. Its expanding portfolio of instruments and consumables enables biomedical scientists to analyze and sort cells required for drug discovery, single cell-omics, cloning, antibody discovery, and basic research.

Shenzhen anteland technology Co., Ltd (Anteland) was founded in 2015. It specializes in the R&D, manufacturing, and sales services of laser direct imaging equipment. After years of R&D investment, the company has reached domestic and international advanced level in the field of micro/submicron lithograph technology. It has become the creator and leader of DFAI technology, which is applied in the field of maskless micro/submicron lithograph technology.

Libra Therapeutics, Inc. operates as a biotechnology company that develops novel disease-modifying therapeutics and drug candidates for restoring the cellular balance disrupted in neurodegenerative diseases. The company’s therapeutic platform discovers and develops small molecule drugs to attenuate the production of neurotoxic proteins for the treatment of amyotrophic lateral sclerosis, frontotemporal dementia, Alzheimer's, Parkinson's, and Huntington's disease. The company was founded in 2019 and is based in San Diego, California.

C4 is building on the knowledge with synthetic chemical compounds which it calls Degronimids. These compounds can be engineered and linked together to bind with many molecular targets that today’s drugs can’t bind with, Cohen said. The key insight, he said, is that the scientific founders have discovered a way to bind with select disease-causing proteins, and flag them as cellular trash, so that the ordinary proteasome garbage disposal system can get rid of them. Selecting the precise disease-related proteins to send to the trash is obviously critical, because any drug like this could cause serious side effects if it sent healthy proteins involved in normal cell processes to the trash. C4 Therapeutics is developing a new class of targeted protein degradation (TPD) therapeutics for the treatment of a broad range of diseases. Our Degronimid™ platform incorporates highly selective small molecule binders to target disease-causing proteins and facilitate their rapid destruction and clearance from the cell through the natural ubiquitin/proteasome system (UPS). Because of this distinctive mechanism, Degronimids are capable of hitting many more targets, including those previously thought to be undruggable, while reducing the potential for drug resistance. The broad applicability of Degronimids, and our chemical biology platform designed for accelerated validation, have the potential to make an unprecedented impact across many diseases through multiple industry collaborations as well as proprietary programs. The Company has received an exclusive worldwide license to the Degronimid platform and related IP from Dana-Farber.

HistoSonics provides the Edison Platform, which uses advanced imaging and proprietary sensing technology to deliver non-invasive, personalized treatments with precision and control, and uses the science of histotripsy and focused sound energy to generate pressures to liquify and completely destroy targeted tissues at sub-cellular levels.

Regenacy Pharmaceuticals they give services to treat diabetic and other peripheral neuropathies.

EvolveImmune Therapeutics develops an immunobiological platform that delivers both sustained immune activation and tumor cell targeting in a single agent. Through integrated signaling, EVs first in category biologics directly target tumor cells and provide potent, tissue-localized amplification of cytokine secretion at the tumor site to maximize tumor killing. The company's biotherapeutics are engineered to overcome the limitations of conventional CD3 bispecific and other immune therapies to offer a better future for our patients in need, by maximizing therapeutic benefit and minimizing toxicity.

Metabomed designs drugs designed treats cancer. Its drugs target the reprogrammed cancer cell's metabolism to halt their growth, enabling patients to begin their treatment more quickly and result in a higher likelihood of a successful treatment.

Frequency Therapeutics develops small molecule drugs that activate progenitor cells within the body to restore healthy tissue. Through the transitory activation of these progenitor cells, Frequency enables disease modification without the complexity of genetic engineering. It was founded in 2015 and headquartered in Woburn, Massachusetts.

Decipher Biosciences offers a portfolio of genomic tests, continues to build the GRID database of over 70,000 whole transcriptome profiles, and is partnering with pharmaceutical companies to identify biomarkers of response to novel therapeutics.

Mesa Biotech simplifies DNA testing. The Mesa Biotech team has achieved a dramatic simplification in the complexity of DNA and RNA molecular testing. Mesa Biotech is based in sunny San Diego, California with a satellite testing laboratory in Santa Fe, New Mexico.

TARIS Biomedical develops new therapies designed for the treatment of difficult-to-treat bladder diseases. The company's system is designed to continuously release drugs in the bladder over weeks to months and is deployed and retrieved using minimally-invasive, in-office procedures, enabling drug release to be tailored to match the needs of each disease.